Spondyloarthropathies
Conference Coverage
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
Patients with axial spondyloarthritis and psoriatic arthritis who used JAK inhibitors did not have higher risk of myocardial infarction or stroke...
Feature
Axial spondyloarthritis versus axial psoriatic arthritis: Different entities?
Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they’re different diseases or on the same spectrum is...
Conference Coverage
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
Among nearly one in four patients whose MRI results were initially positive for sacroiliitis, results were negative 6 weeks after NSAIDs were...
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Feature
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
Conference Coverage
Expert offers caveats to perioperative antirheumatic drug guideline
Experts say the 2022 ACR/AAHKS guideline on perioperative management of antirheumatic medications in total hip and total knee arthroplasty have a...
Latest News
New influx of Humira biosimilars may not drive immediate change
As many as 8-10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.
Conference Coverage
Biosimilars perform identically to originator biologics in natural experiment
A real-world analysis of the impact of biosimilar switches over 3 years of follow-up addresses the limitations of formal trials in assessing...
Latest News
First Humira biosimilar launches in U.S.
Amgen’s Amjevita will be offered at 5% and 55% below Humira’s list price, but patients may not benefit from the more significant discount.